We use our own and third party cookies in order to improve our performance, and to obtain anonymous statistics about the use of the website. By continuing to browse, you authorize their use. In order to change the preferences and to obtain further information, please refer to our cookies policy.

Areas
Menu
en

Our Scientific Focus

Today, LETI is positioned as one of the leading companies in the area of leishmaniasis research. With over twenty years of experience, and several antigens and adjuvants in our pipeline, our goal is to deliver several much needed vaccine and diagnostic candidates to clinic, and ultimately to market.

Our commitment to the development of vaccines for human and canine leishmaniasis stems from an awareness of the tremendous unmet need for solutions for this life-threatening and disabling condition.

We currently have nine research projects and three clinical candidates in our portfolio. Our patents extend beyond leishmaniasis and into other protozoan infections.

In addition to our work in leishmaniasis, our research has expanded to include novel adjuvants that can play an ancillary role in targeting inflammation, cancer, parasitic infections and other autoimmune diseases.

Through cutting-edge technology LETI is:

  • Discovering lead candidates through state-of-the-art techniques
  • Accelerating the development of novel vaccines
  • Engineering innovative adjuvants

At LETI, we are constantly seeking innovative ways to bring improvements to the unmet healthcare needs of people suffering from diseases that are rare, neglected, or without adequate preventive or therapeutic solutions.

Our focus is to work collaboratively with research centers, public entities, governmental organizations, and other interested parties to provide the best possible solutions for the disease areas we are passionate about.

Our Scientific Focus - Leishmaniasis

Leishmaniasis is one of the major infectious diseases afflicting the world's poorest populations. It represents a complex of symptoms which have important clinical, epidemiological, and public health implications.

Leishmaniasis is endemic in 88 countries, with more than 350 million people at risk. It affects both tropical and sub-tropical regions of the Old and New World, as well as developed regions of Western Europe. Leishmaniasis affects both humans and animals. In humans, approximately 10 to 12 million people are infected--with an estimated incidence of 2 million new cases per year, 500,000 of which present in the visceral form and 1.5 million in the cutaneous or mucocutaneoous forms.

Visceral Leishmaniasis, the most fatal of forms, causes an estimated 59,000 deaths annually--a rate surpassed among parasitic diseases only by malaria. (1)

For those that survive a Leishmaniasis infection, the human impact of the disease can be tremendous—it is estimated that 2,357,000 disability-adjusted life years (DALYs) are lost due to the disease, placing leishmaniasis 9th in a global analysis of infectious diseases. (2)

References of interest:

(1) Desjeux, P., 2004. Leishmaniasis: current situation and new perspectives. Comp. Immunol., Microbiol. Infect. Dis. 27, 305-318.

(2) The World Health Organization webpage